Healint’s Migraine Buddy app / Photo credit: Healint

US-listed Aptar Digital Health has acquired Healint, a Singapore-based healthtech firm, for an undisclosed amount.

“This acquisition will accelerate the development of our AI-powered precision medicine SaMD, [which is] designed to augment existing treatment,” said François Cadiou, Healint’s founder and CEO, in a statement.

Following the deal, Healint’s services will be integrated into Aptar’s operations.

Founded in 2013, Healint is the company behind Migraine Buddy, a migraine tracking app it launched in 2014. The app, which helps patients understand their condition through sensor readings, has over 3 million registered users.

The firm also has another app called Clarrio, which assists users with chronic pain management.

According to Tech in Asia’s database, the company has raised US$1.2 million in disclosed funding. Backers include Wavemaker Partners, Strive, and the Singapore National Research Foundation.

Healint reported US$2.2 million in revenue for the 2023 financial year, a 33% increase from the previous year, according to data from Alternatives.pe, which monitors regulatory filings in Singapore. It recorded a positive EBIT of US$74,000 in the same period, down from US$1.3 million in FY 2022.

On Alternatives.pe, the company’s post-money valuation is listed at US$2.9 million. However, the number may not consider the full picture – such as investments from convertible debt – which would give Healint a higher valuation.

Cadiou told Tech in Asia that these financial and post-money valuation figures are “pretty wrong” but declined to comment further.

Meanwhile, Aptar provides end-to-end solutions connecting drug delivery systems, onboarding, training, and advanced data analytics services for patients. The company, which has 13,000 employees across 20 countries, says the Healint acquisition will help expand its global presence, among other things.

Aptar also plans to introduce new services like clinical trial management tools following the deal.

See also: KonsultaMD tapped an ‘unfair advantage’ to grow. Can it become a leading healthtech player?